Amneal Pharmaceuticals expects to meet or exceed its 2024 financial guidance, projecting net revenue of $2.70 billion to $2.80 billion and adjusted EBITDA of $610 million to $630 million, with an estimated net leverage of approximately 4x as of December 31, 2024.